|
US2013178449A1
|
|
2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs
|
|
US2012283227A1
|
|
(20R) and (20S)-24-(p-toluenesulfonyloxy)-25,26,27-trinorvitamin D3 analogs and their uses
|
|
US2012165300A1
|
|
Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
|
|
US2012149669A1
|
|
22-haloacetoxy-homopregnacalciferol analogs and their uses
|
|
US2012157418A1
|
|
2-methylene-19-nor-vitamin D analogs and their uses
|
|
US2011082122A1
|
|
19-nor-vitamin D analogs with 1,2- or 3,2-cyclopentene ring
|
|
US2009281340A1
|
|
1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof
|
|
US2010009940A1
|
|
2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
|
|
US2010009946A1
|
|
2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs
|
|
US2010009947A1
|
|
2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs
|
|
US2008300223A1
|
|
(20R)-2α-methyl-19,26,2-trinor-vitamin D analogs
|
|
US2009004133A1
|
|
Methods and compositions for phosphate binding
|
|
US2008249068A1
|
|
Method of Extending the Dose Range of Vitamin D Compounds
|
|
US2008021002A1
|
|
Vitamin d compounds used to stabilize kidney transplants
|
|
US2007238704A1
|
|
2-substituted-1α,25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof
|
|
US2007244072A1
|
|
1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof
|
|
US2007071715A1
|
|
Methods and compositions for phosphate binding
|
|
US2006189532A1
|
|
Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
|
|
US2006079490A1
|
|
Method of treatment of type I diabetes
|
|
US2005143358A1
|
|
Methods for reducing body fat using vitamin D compounds
|
